Parmley, William W.
December 1977
Angiology;Dec1977, Vol. 28 Issue 12, p865
Academic Journal
The pathophysiology of angina pectoris is best understood as an imbalance between oxygen supply and demand. The primary determinants of myocardial oxygen demand are heart rate, arterial pressure, heart size, myocardial contractility, and myocardial mass. The medical therapy of angina pectoris is directed toward reducing myocardial oxygen demand by reducing the workload of the heart and the specific determinants listed. The most common medications used in the treatment of angina pectoris are nitroglycerin and propranolol. Nitroglycerin reduces myocardial oxygen demand primarily by reducing heart size and arterial pressure. Propranolol reduces oxygen demand primarily by reducing heart rate. Medical therapy is generally effective in controlling the symptoms of angina pectoris in 80% or more of the patients and allows them to lead useful and productive lives.


Related Articles

  • Improving Red Blood Cell K-Uptake and its Impact on O2/CO2 Exchange, and NO-Generation in Microvascular CHD: A Novel Therapeutic Approach. Delgado-Almeida, Antonio // Recent Patents on Cardiovascular Drug Discovery;Nov2010, Vol. 5 Issue 3, p227 

    Coronary heart disease (CHD) is the leading cause of morbidity and mortality across the entire world. In effect, reversion of angina or improvement of ECG remains an unrealistic therapeutic option for most patients. Unfortunately, most research clinical trials in these patients have focused on...

  • BOX 12-1 CORONARY ARTERY DISEASE. Scanlon, Valerie C.; Sanders, Tina // Essentials of Anatomy & Physiology;Jan2007, p280 

    Information on coronary artery disease from Chapter 12 of the book "Essentials of Anatomy & Physiology" is presented. It discusses the pathology of the disease and its two different types, angina and myocardial infarction. It offers information on atherosclerosis, including its risk factors and...

  • Differential Benefits and Outcomes of Tirofiban vs Abciximab for Acute Coronary Syndromes in Current Clinical Practice. Gowda, Manohar S.; Vacek, James L.; Lakkireddy, D.J.; Brosnahan, Kathleen; Beauchamp, Gary D. // Angiology;Mar/Apr2003, Vol. 54 Issue 2, p211 

    Little comparative data exist for glycoprotein IIb/IIIa inhibitors in acute coronary syndromes (ACS). Two hundred twenty-eight patients were studied: 114 received tirofiban (TI) and 114 received abciximab (AB) for either unstable angina (UA) or myocardial infarction (MI). All patients received...

  • Preclinical and Clinical Pharmacology of Efegatran (LY294468): A Novel Antithrombin for the Treatment of Acute Coronary Syndromes. Jackson, Charles V.; Satterwhite, Julie; Roberts, Eiry // Clinical & Applied Thrombosis/Hemostasis;Fall1996, Vol. 2 Issue 4, p258 

    Efegatran (LY294468), a tripeptide arginal inhibitor of the catalytic site of thrombin, is being developed as a parenteral anticoagulant for the treatment of acute coronary syndromes. Efegatran was studied in a canine model of coronary artery thrombosis to determine its ability to prevent...

  • On heart attacks. Hensrud, Donald D. // Fortune;2/18/2002, Vol. 145 Issue 4, p156 

    Provides information on heart attacks. Description of angina, which occurs when blood flow in one of the arteries that supply the heart is decreased because of a buildup of plaque; Mistake of not seeking immediate medical attention after a heart attack; How aspirin can help reduce the risk of...

  • Are there socioeconomic differences in myocardial infarction event rates and fatality among patients with angina pectoris? Manderbacka, Kristiina; Hetemaa, Tuna; Keskimäki, Limo; Luukkainen, Pekka; Koskinen, Seppo; Reunanen, Antti // Journal of Epidemiology & Community Health;May2006, Vol. 60 Issue 5, p442 

    Background: Systematic socioeconomic differences in mortality have been reported among myocardial infarction (MI) patients in many countries, including Finland. The findings have been similar irrespective of country, study period, age group, or length of follow up, but few studies have examined...

  • Megakaryoblastic leukemia factor-1 gene in the susceptibility to coronary artery disease. Hinohara, Kunihiko; Nakajima, Toshiaki; Yasunami, Michio; Houda, Shigeru; Sasaoka, Taishi; Yamamoto, Ken; Bok-Soo Lee; Shibata, Hiroki; Tanaka-Takahashi, Yumiko; Takahashi, Megumi; Arimura, Takuro; Sato, Akinori; Naruse, Taeko; Jimin Ban; Inoko, Hidetoshi; Yamada, Yoshiji; Sawabe, Motoji; Park, Jeong-Euy; Izumi, Toru; Kimura, Akinori // Human Genetics;Oct2009, Vol. 126 Issue 4, p539 

    Coronary artery disease (CAD) is based on the atherosclerosis of coronary artery and may manifest with myocardial infarction or angina pectoris. Although it is widely accepted that genetic factors are linked to CAD and several disease-related genes have been reported, only a few could be...

  • A 3-year follow-up study of coronary heart disease in Delhi. Chadha, S. L.; Ramachandran, K.; Shekhawat, S.; Tandon, R.; Gopinath, N. // Bulletin of the World Health Organization;1993, Vol. 71 Issue 1, p67 

    A follow-up study of coronary heart disease (CHD) was carried out among adults in Delhi 3 years after an initial community-based epidemiological survey of the same population. A total of 575 of the 814 cases of CHD detected clinically and by electrocardiogram (ECG) in the initial survey took...

  • Ask Dr. Zipes. Zipes, Douglas P. // Saturday Evening Post;Mar/Apr2010, Vol. 282 Issue 2, p68 

    The article presents answers to several health-related questions including what causes high blood pressure in persons whose heart tests are normal, whether a person with angina is at risk for a heart attack, and whether a person who died in his sleep of a massive heart attack could have been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics